Recent News

  • Mixed Drinks, Mixed Results (10.30.2026)

    Jack Cush, MD
    RheumNow Podcast square

    Dr. Cush reviews the news and journal reports from this past week on RheumNow. This week on the podcast: hopeful guidelines for PMR; certainty about good & bad beverages in gout; mixed results in Sjogren's; non-lupus drugs saves lupus lives; and big hips sink ships in psoriatic arthritis.

    Read Article
Dr. John Cush Tweet
@RheumNow
JAMA Uveitis review: Uveitis peaks at 20–50 yrs; 41–60% is anterior. ~40 linked to systemic disease (HLA-B27=axSpA). 1st exclude infection (TB, toxo, herpes). Anterior UV: topical steroids. Posterior/pan UV: DMARDs first (MTX remission 52%, MMF 71%); adalimumab if refractory https://t.co/xTlr5lrwUz
sheila Tweet
@RHEUMarampa
Optimizing GC use in SLE: In arthritis, avoid oral GC - consider NSAIDS, csDMARDs, small molecules or biologics On GC initiation, hit hard w/pulse MP then taper early and rapidly In LN, treat aggressively bec damage is driven by dse activity, not meds @RheumNow #APLAR2026 https://t.co/Q5gFpr8P9k
Dr. John Cush Tweet
@RheumNow
Dr. Cush reviews the news and journal reports from this past week on RheumNow. This week on the podcast: hopeful guidelines for PMR; certainty about good & bad beverages in gout; mixed results in Sjogren's; non-lupus drugs saves lupus lives; and big hips sink ships in psoriatic https://t.co/TPqPKP5MRl
Dr. John Cush Tweet
@RheumNow
Advances and Challenges in Lupus Care: Insights from RheumNow Survey Findings Listen to leading rheumatology and dermatology experts for an engaging discussion on the evolving landscape of Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE). https://t.co/lJOzeR81AS
Dr. John Cush Tweet
@RheumNow
The Efficacy of Ianalumab in Sjögren’s Disease The NEPTUNUS-1 and NEPTUNUS-2 trials have showed that monthly ianalumab is superior of placebo at improving Sjögren’s disease activity at week 48, even though there was no significant ESSDAI response or in the change in SSSD or https://t.co/YStzIFq5Bx
Dr. John Cush Tweet
@RheumNow
Tx persistence & response in PsA is a problem - influenced by demographics & Dz severity. 815 PsA pts in e Brit Society Rheumatology PsA Registe. @12 mos - 24% MDA, 24% ACR50. Median F/U 31 mos, only 65% still on index Rx. D/C higher w/ PDE4i & poorer baseline activity & PROs https://t.co/BhxAMtjsZV
Peter Nash Tweet
@drpnash
Schett : in vivo the future if it works, during LD aciclovir, co-trimoxazole, CAR-T expansion amount not associated with toxicity, 3 month no vaccination window, all tissues B cell depletion , naive b cells return APLAR Seoul 2026 #CART #RheumNow
Peter Nash Tweet
@drpnash
number of naive-like CAR-T infused associates with prolonged survival but highly variable APLAR Seoul 2026 #CAR-T #Rheum Now

Video

Podcasts

  • Mixed Drinks, Mixed Results (10.30.2026)
  • Advances and Challenges in Lupus Care: Insights from RheumNow Survey Findings
  • Double Trouble (10.23.2026)
  • Troubles with ‘Gut Feelings’
Ask Cush Anything

Submit your Rheumatology question or case here

Therapeutic Updates

Clinical dilemmas in axSpA and PsA

Sponsored by UCB
UCB October RX Update
Explore some of the challenges rheumatologists face in clinical practice, including expert perspectives from UCB's Annual International Immunology Summit.
Read Post

PsA Beyond the Joints: Rheum, Derm, and Gastro Perspectives

Sponsored by AbbVie Medical Affairs + Health Impact
AbbVie October RX Update
Dr. Saakshi Khattri hosts dermatologist Dr. Ahmad Amin and gastroenterologist Dr. Joshua Steinberg to discuss multidisciplinary care in PsA and other immune-mediated inflammatory diseases. Learn how signals in the skin and gut may prompt the need for collaboration across specialties to support better patient outcomes that extend beyond the joints.
Read Post

Obesity – Inflammation – PsA

Sponsored by Lilly Medical Affairs
Lilly October
Learn about the inflammatory intersection between Psoriatic Arthritis and Obesity, and why adiposity is more than a comorbidity.
Read Post
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×